KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Halozyme Therapeutics (HALO) over the last 16 years, with Q3 2025 value amounting to $20.3 million.

  • Halozyme Therapeutics' Other Working Capital Changes rose 15279.99% to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.8 million, marking a year-over-year increase of 370361.53%. This contributed to the annual value of -$5.4 million for FY2024, which is 3069.79% down from last year.
  • Per Halozyme Therapeutics' latest filing, its Other Working Capital Changes stood at $20.3 million for Q3 2025, which was up 15279.99% from $36.1 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Other Working Capital Changes high stood at $43.5 million for Q2 2024, and its period low was -$38.5 million during Q3 2024.
  • Moreover, its 5-year median value for Other Working Capital Changes was $2.3 million (2021), whereas its average is $3.8 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Other Working Capital Changes tumbled by 332384.11% in 2023, and later surged by 99447.41% in 2024.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Other Working Capital Changes stood at $5.0 million in 2021, then tumbled by 205.02% to -$5.3 million in 2022, then skyrocketed by 122.68% to $1.2 million in 2023, then plummeted by 568.03% to -$5.6 million in 2024, then soared by 461.48% to $20.3 million in 2025.
  • Its Other Working Capital Changes was $20.3 million in Q3 2025, compared to $36.1 million in Q2 2025 and $5.0 million in Q1 2025.